Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and poor prognosis due to red blood cell transfusion–dependent anemia and thrombocytopenia
Garcia-Manero, Guillermo, Almeida, Antonio, Giagounidis, Aristoteles, Platzbecker, Uwe, Garcia, Regina, Voso, Maria Teresa, Larsen, Stephen R., Valcarcel, David, Silverman, Lewis R., Skikne, Barry, SaТом:
16
Мова:
english
Журнал:
BMC Hematology
DOI:
10.1186/s12878-016-0049-5
Date:
December, 2016
Файл:
PDF, 555 KB
english, 2016
File converter
Більше результатів пошуку
More benefits 
